Loading resource…

Japanese Society on Thrombosis and Hemostasis
The guidelines address the complexities of DIC in patients with solid cancers, highlighting the variability in severity and bleeding tendencies based on cancer type and stage. The document emphasizes the need for careful monitoring when administering anticoagulant therapy due to the risks of major bleeding. It also discusses the lack of high-quality research on DIC related to solid cancers and presents recommendations for clinical questions regarding treatment options such as heparin and recombinant thrombomodulin.
No account needed
Answers use this document only.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

SICKLECELL GUIDELINES 2025 (2)
Same clinical topic · Hematology

AMERICAN SOCIETY OF HEMATOLOGY 2026 GUIDELINES FOR DIAGNOSIS OF IRON DEFICIENCY
Same clinical topic · Hematology

Guideline for SCD Management - Uganda (2)
Same clinical topic · Hematology

SICKLECELL GUIDELINES 2025-2030
Same clinical topic · Hematology

MANAGEMENT OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT)
Same clinical topic · Hematology

AMERICAN SOCIETY OF HEMATOLOGY 2026 GUIDELINES FOR IMMUNE THROMBOCYTOPENIA (ITP): INITIAL AND SECOND-LINE THERAPY IN ADULTS WITH PRIMARY ITP
Same clinical topic · Hematology

AMERICAN SOCIETY OF HEMATOLOGY 2026 GUIDELINES FOR IMMUNE THROMBOCYTOPENIA (ITP): INITIAL AND SECOND-LINE THERAPY IN ADULTS WITH PRIMARY ITP
Same clinical topic · Hematology

AMERICAN SOCIETY OF HEMATOLOGY 2021 GUIDELINES FOR SICKLE CELL DISEASE: STEM CELL TRANSPLANTATION
Same clinical topic · Hematology

GUIDELINES FOR THE MANAGEMENT OF EMERGENCIES AND CRITICAL ILLNESS IN PEDIATRIC AND ADULT PATIENTS WITH SICKLE CELL DISEASE
Same clinical topic · Hematology